6.05 USD
+0.15
2.54%
At close Dec 23, 4:00 PM EST
1 day
2.54%
5 days
4.31%
1 month
4.31%
3 months
13.94%
6 months
21.73%
Year to date
-1.79%
1 year
-0.49%
5 years
-11.03%
10 years
68.06%
 

About: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Employees: 378

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $32M [Q2] → $34.8M (+$2.79M) [Q3]

0.08% more ownership

Funds ownership: 11.19% [Q2] → 11.26% (+0.08%) [Q3]

0% more funds holding

Funds holding: 30 [Q2] → 30 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

99% less call options, than puts

Call options by funds: $2K | Put options by funds: $139K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
82%
upside
Avg. target
$11
82%
upside
High target
$11
82%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
30% 1-year accuracy
100 / 328 met price target
82%upside
$11
Buy
Reiterated
14 Nov 2024

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript
Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd.
Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
REHOVOT, Israel and HOBOKEN, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
Neutral
Seeking Alpha
4 months ago
Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to Kamada Limited Second Quarter 2024 Earnings Conference Call.
Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024.
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Positive
InvestorPlace
4 months ago
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
Neutral
Seeking Alpha
7 months ago
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conference Call.
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
7 months ago
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Neutral
GlobeNewsWire
7 months ago
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Neutral
Seeking Alpha
9 months ago
Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET
Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
9 months ago
Kamada Issues 2024 CEO Letter to Shareholders
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer.
Kamada Issues 2024 CEO Letter to Shareholders
Charts implemented using Lightweight Charts™